GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. See why I think ...

Twist Exome 2.0适用于罕见病和遗传病以及癌症胚系变异的检测。该组合均一性高，脱靶率低，能够提供一流的测序效率，让您只需较少的测序即可获取高质量的数据。 Twist Exome 2.0 覆盖了包括RefSeq、CCDS、GenCode、Clinvar、ACMG73 等主要遗传数据库，并增加了与临床相关 ...

Scientists at the Icahn School of Medicine at Mount Sinai and collaborators have identified novel genetic interactions that may contribute to congenital heart disease (CHD), a common birth defect.

Genetic testing platform PleSSision-Exome, a DNA sequencing system that covers more than 19,000 different genes, could help expand personalized cancer medicine in Japan. Developed by Hiroshi ...

GeneDx Holdings Corp (WGS) reports robust revenue growth and unveils new products, despite facing reimbursement challenges.

GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.

President and CEO Katherine Stueland stated that GeneDx achieved significant milestones in 2024, including surpassing $95 million in Q4 revenue and expanding gross margins to 70%. She highlighted the ...

The pipeline utilizes several external databases as illustrated in the figure. The sources of these databases are summarized in the table below. The test data provided in this documentation ...

GeneDx stock catapulted Tuesday after the top-notch biotech smashed fourth-quarter expectations and issued upbeat guidance.